TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)
Brief Summary: This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab
B: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
C: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)
Brief Summary: This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg
B: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4
C: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)
Brief Summary: This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg
C: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg
D: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individual Placement and Support (IPS) Enhanced With Cognitive Remediation and Social Skills Training in Denmark: a Randomized Controlled Trial
Brief Summary: The purpose of this study is to investigate the efficacy of IPS in Denmark and compare effects of 1. Individual Placement and Support (IPS) vs. 2. IPS + cognitive remediation and work-related social skills training vs. 3. standard intervention, among individuals with severe mental illness.


Options:
A: Arm Label: Individual Placement and Support (IPS); Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and support (IPS) | Arm Label: IPS plus; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and support (IPS), Behavioral: IPS plus | Arm Label: Standard intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Individual Placement and support (IPS); Assigned to Arm(s): IPS plus, Individual Placement and Support (IPS) | Intervention Type: BEHAVIORAL; Name: IPS plus; Assigned to Arm(s): IPS plus
B: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes
C: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Training | Arm Label: Standard Pharmacotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive enhancement therapy (CET) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Enriched supportive therapy (EST) | Intervention Type: BEHAVIORAL; Name: Cognitive enhancement therapy (CET); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enriched supportive therapy (EST); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Assessment of the effect of hyperoxia and hypertonic saline on survival in patients with septic shock Hyperoxia and hypertonic saline may have beneficial effects on organ perfusion and oxygenation and may reduce the organ failure occurences. To date, only scarce data are available. Side effects are not well described. Therefore we designed a randomized clinical trial in order to assess the early administration of hypertonic saline and oxygen in the very early beginning of septic shock.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): A, B
B: Arm Label: normoxia and isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: oxygen and saline | Arm Label: normoxia and 3% hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxygen and saline | Arm Label: hyperoxia and isotonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxygen and saline | Arm Label: hyperoxia and 3% hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxygen and saline | Intervention Type: DRUG; Name: oxygen and saline; Assigned to Arm(s): hyperoxia and 3% hypertonic saline, hyperoxia and isotonic saline, normoxia and 3% hypertonic saline, normoxia and isotonic saline
C: Arm Label: Oxygen reduction; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen reduction, Standard Care
D: Arm Label: Nasal oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal oxygen | Arm Label: Nasal Air; Type: PLACEBO_COMPARATOR; Interventions: Drug: Regular nasal air | Intervention Type: DRUG; Name: Nasal oxygen; Assigned to Arm(s): Nasal oxygen | Intervention Type: DRUG; Name: Regular nasal air; Assigned to Arm(s): Nasal Air

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Brief Summary: A study to show the safety of COV155 in patients with osteoarthritis of the knee or hip or moderate to severe chronic low back pain.


Options:
A: Arm Label: COV155; Type: EXPERIMENTAL; Interventions: Drug: COV155 | Intervention Type: DRUG; Name: COV155; Assigned to Arm(s): COV155
B: Arm Label: LAYLA; Type: EXPERIMENTAL; Interventions: Drug: LAYLA tablet | Arm Label: JOINS; Type: ACTIVE_COMPARATOR; Interventions: Drug: JOINS tablet | Intervention Type: DRUG; Name: LAYLA tablet; Assigned to Arm(s): LAYLA | Intervention Type: DRUG; Name: JOINS tablet; Assigned to Arm(s): JOINS
C: Arm Label: Huo-Luo-Xiao-Ling; Type: ACTIVE_COMPARATOR; Interventions: Drug: HLXL | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: HLXL | Intervention Type: DRUG; Name: HLXL; Assigned to Arm(s): Huo-Luo-Xiao-Ling, Placebo
D: Arm Label: Tramadol Hydrochloride/Acetaminophen ER; Type: EXPERIMENTAL; Interventions: Drug: Tramadol HCl/Acetaminophen ER | Arm Label: Tramadol HCl/Acetaminophen IR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tramadol HCl/Acetaminophen IR | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen ER; Assigned to Arm(s): Tramadol Hydrochloride/Acetaminophen ER | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen IR; Assigned to Arm(s): Tramadol HCl/Acetaminophen IR

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Inspiratory Oxygen Fraction - Effect on Occurrence of Subsequent Cancer After Abdominal Surgery (Follow-up of the PROXI Trial)
Brief Summary: Aim: to investigate the effect of a high inspiratory oxygen fraction (FiO2) given during and after laparotomy procedures on occurrence of a subsequent, new or recurrent, cancer diagnosis at a long-term follow-up.

Background: A high inspiratory oxygen fraction (FiO2 = 0.80) has been linked to prevention of surgical site infection, but the Danish randomized clinical multicenter trial, the PROXI trial, found no difference in frequency of surgical site infection. In fact, long-term mortality was significantly increased with a hazards ratio of 1.30 in patients receiving 80% oxygen, and this appeared to be statistically significant in patients undergoing cancer surgery, but not in non-cancer patients.

At this point, no convincing mechanism explains the observed increased mortality after hyperoxia, as the long-term pathophysiological effects of oxygen are not fully understood.

Primary hypothesis of this follow-up study of the PROXI trial: Use of 80% oxygen increase the frequency of patients with a subsequent, new or recurrent, cancer.


Options:
A: Arm Label: Post op care; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen delivery, Other: Oxygen administration | Arm Label: Oxygen administration- different %; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen administration | Intervention Type: OTHER; Name: Oxygen delivery; Assigned to Arm(s): Post op care | Intervention Type: OTHER; Name: Oxygen administration; Assigned to Arm(s): Oxygen administration- different %, Post op care
B: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: 80% oxygen group; Type: N/A; Interventions: Drug: Oxygen | Arm Label: 30% oxygen group; Type: N/A; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): 30% oxygen group, 80% oxygen group
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments
Brief Summary: This study compares treatment of Neonatal Abstinence Syndrome (NAS) with two different drugs for the difference in the length of treatment. This is a randomized, open-label comparison of phenobarbital and methadone versus phenobarbital and diluted deodorized tincture of opium (dDTO) where phenobarbital is the initial drug used to stabilize neonatal withdrawal.


Options:
A: Arm Label: 1 (Phenobarbital and Methadone); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: 2 (Phenobarbital and Diluted Deodorized Tincture of Opium); Type: ACTIVE_COMPARATOR; Interventions: Drug: Diluted Deodorized Tincture of Opium | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1 (Phenobarbital and Methadone) | Intervention Type: DRUG; Name: Diluted Deodorized Tincture of Opium; Assigned to Arm(s): 2 (Phenobarbital and Diluted Deodorized Tincture of Opium)
B: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
C: Arm Label: sublingual buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: sublingual buprenorphine | Arm Label: oral morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral morphine | Intervention Type: DRUG; Name: sublingual buprenorphine; Assigned to Arm(s): sublingual buprenorphine | Intervention Type: DRUG; Name: oral morphine; Assigned to Arm(s): oral morphine
D: Arm Label: Oral morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Oral morphine sulfate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Intervention in Infants
Brief Summary: The study is a randomized, controlled, double blinded study evaluating the effect of recommended (400 IU) and 1 200 IU daily vitamin D substitution, given from 2 weeks to 2 years of age, on growth, bone development, neurologic and cognitive development, frequence of infectious diseases, allergic symptoms, and development of immunoregulation assessed at 2 years of age.


Options:
A: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A
B: Arm Label: Vitamin D supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 10 ug/day | Arm Label: Vitamin D supplement at 30 ug/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 30 ug/day; Assigned to Arm(s): Vitamin D supplement at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 10 ug/day; Assigned to Arm(s): Vitamin D supplement
C: Arm Label: 200 IU/day Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 400 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 600 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 800 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day; Assigned to Arm(s): 200 IU/day Vitamin D, 400 IU/day Vitamin D, 600 IU/day Vitamin D, 800 IU/day Vitamin D
D: Arm Label: Vitamin D 150,000 units once; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Vitamin D 5000 units daily; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D 150,000 units once | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D 5000 units daily

Answer: B